- Trials with a EudraCT protocol (56)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
56 result(s) found for: Egg donation.
Displaying page 1 of 3.
EudraCT Number: 2017-004433-93 | Sponsor Protocol Number: RIOTCSTUDY22017 | Start Date*: 2018-05-01 | ||||||||||||||||
Sponsor Name:Nicholas Stephen Macklon, Professor, MD, PhD | ||||||||||||||||||
Full Title: RIOT C: REDUCING THE IMPACT OF OVARIAN STIMULATION. NOVEL APPROACHES TO LUTEAL SUPPORT IN IVF. STUDY 2. | ||||||||||||||||||
Medical condition: Ovarian stimulation in oocyte donation | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Female | |||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-000821-37 | Sponsor Protocol Number: GS-US-416-2124 | Start Date*: 2017-02-06 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Phase 2, Double-Blind, Randomized Study Evaluating the Safety, Tolerability, and Efficacy of GS-4997 in Combination with Prednisolone versus Prednisolone Alone in Subjects with Severe Alcoholic H... | |||||||||||||
Medical condition: Alcoholic Hepatitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) BE (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001743-20 | Sponsor Protocol Number: 1403-MAD-013-AR | Start Date*: 2015-07-30 |
Sponsor Name:IVI Madrid | ||
Full Title: A Multicentre, prospective, randomised clinical trial comparing the cost and efficacy of corifolitropina alfa vs Recombinant FSH and / or HP-hMG | ||
Medical condition: The study is proposed to determine the level of compliance and pharmacoeconomic impact of three protocols for controlled ovarian stimulation in women participating in oocyte donation program | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2007-000212-89 | Sponsor Protocol Number: antagovo | Start Date*: 2008-03-04 |
Sponsor Name:Instituto Universitario IVI Valencia | ||
Full Title: Uso de antagonistas de la GnRH en la preparación endometrial de las receptoras de ovocitos. | ||
Medical condition: Comparar los resultados obtenidos con el empleo de antagonistas de la GnRH en la sincronización receptora de ovocitos–donante frente a los resultados obtenidos con el tradicional empleo de supresió... | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2014-004489-85 | Sponsor Protocol Number: MORAb-009-201 | Start Date*: 2015-11-03 | |||||||||||
Sponsor Name:Morphotek Inc | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Amatuximab in Combination with Pemetrexed and Cisplatin in Subjects with Unresectable Malignant Pleural Mesothelioma | |||||||||||||
Medical condition: Advanced pleural mesothelioma | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004418-16 | Sponsor Protocol Number: B24CS | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Advicenne SA | |||||||||||||
Full Title: A Phase 3b Open-Label Extension of Study B23CS (ARENA 2) Evaluating the Continued Safety and Efficacy of ADV7103 in Subjects With Primary Distal Renal Tubular Acidosis (ARENA 2 Open-label Extensio... | |||||||||||||
Medical condition: Distal renal tubular acidosis | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000436-62 | Sponsor Protocol Number: GS-US-380-4547 | Start Date*: 2021-02-12 |
Sponsor Name:Gilead Sciences, Inc | ||
Full Title: A Phase 1, Single-Dose, Cross-Over Study Evaluating the Relative Bioavailability and Food Effect of a Pediatric Tablet for Oral Suspension of Bictegravir/Emtricitabine/Tenofovir Alafenamide and the... | ||
Medical condition: Human Immunodeficiency Virus (HIV-1) Infection | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2022-001677-31 | Sponsor Protocol Number: AMB-001 | Start Date*: 2022-10-28 | |||||||||||
Sponsor Name:Aarhus University Hospital | |||||||||||||
Full Title: Administration of the BCL-2 antagonist, venetoclax, to promote apoptosis of HIV-infected cells and reduce the size of the HIV reservoir: An investigator-initiated phase I/IIb clinical trial in peop... | |||||||||||||
Medical condition: HIV-1 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-001995-23 | Sponsor Protocol Number: NIBIT-MESO-1 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:FONDAZIONE NIBIT NETWORK ITALIANO PER LA BIOTERAPIA DEI TUMORI | |||||||||||||
Full Title: A SINGLE ARM, PHASE II CLINICAL STUDY OF TREMELIMUMAB COMBINED WITH THE ANTI-PD-L1 MEDI4736 MONOCLONAL ANTIBODY IN UNRESECTABLE MALIGNANT MESOTHELIOMA SUBJECTS: NIBIT-MESO-1 STUDY | |||||||||||||
Medical condition: UNRESECTABLE MALIGNANT MESOTHELIOMA | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003951-39 | Sponsor Protocol Number: GS-US-223-1017 | Start Date*: 2019-12-09 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Di... | |||||||||||||
Medical condition: Diabetic Kidney Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) ES (Prematurely Ended) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-003596-30 | Sponsor Protocol Number: MEDI4736-MDS-001 | Start Date*: 2016-05-23 | ||||||||||||||||
Sponsor Name:Celgene International II Sàrl | ||||||||||||||||||
Full Title: A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Hi... | ||||||||||||||||||
Medical condition: Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed) PT (Completed) ES (Ongoing) AT (Completed) DE (Completed) BE (Completed) PL (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2022-000855-35 | Sponsor Protocol Number: HZNP-DAX-204 | Start Date*: 2022-09-23 | |||||||||||
Sponsor Name:Horizon Therapeutics Ireland DAC | |||||||||||||
Full Title: An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Daxdilimab (HZN-7734) in Subjects with Systemic Lupus Erythematosus | |||||||||||||
Medical condition: Systemic Lupus Erythematosus (SLE) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Completed) ES (Prematurely Ended) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000089-45 | Sponsor Protocol Number: OT-15-001 | Start Date*: 2016-11-07 | |||||||||||
Sponsor Name:Orbus Therapeutics, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma That Progress/Recur Af... | |||||||||||||
Medical condition: Anaplastic Astrocytoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) NL (Completed) FR (Completed) IT (Completed) GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-003176-16 | Sponsor Protocol Number: ADP-0055-003/GOG-3084 | Start Date*: 2023-07-03 |
Sponsor Name:Adaptimmune LLC | ||
Full Title: A PHASE 2, OPEN-LABEL, RANDOMIZED, NON-COMPARATIVE CLINICAL TRIAL OF ADP-A2M4CD8 MONOTHERAPY AND IN COMBINATION WITH NIVOLUMAB IN SUBJECTS WITH RECURRENT OVARIAN CANCERS (SURPASS-3 STUDY/ GOG-3084) | ||
Medical condition: Recurrent ovarian cancer positive for MAGE-A4 in human leukocyte antigen (HLA)-A2+ subjects | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: FR (Trial now transitioned) ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-004918-35 | Sponsor Protocol Number: CP-MGA271-06 | Start Date*: 2021-04-08 | |||||||||||
Sponsor Name:MacroGenics, Inc. | |||||||||||||
Full Title: A Phase 2 Open-Label Trial to Evaluate Enoblituzumab in Combination with Retifanlimab or Tebotelimab in the First-Line Treatment of Patients with Recurrent or Metastatic Squamous Cell Carcinoma of ... | |||||||||||||
Medical condition: Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Prematurely Ended) PL (Prematurely Ended) BG (Prematurely Ended) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000783-15 | Sponsor Protocol Number: GP41341 | Start Date*: 2019-05-07 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:Genentech, Inc. | ||||||||||||||||||||||||||||||||||||||
Full Title: A RANDOMIZED, OPEN-LABEL, TWO PART STUDY TO EXPLORE THE PERFORMANCE OF ENTRECTINIB PROTOTYPE MINI-TABLET FORMULATIONS AND THE EFFECT OF DRUG SUBSTANCE PARTICLE SIZE ON ENTRECTINIB BIOAVAILABILITY I... | ||||||||||||||||||||||||||||||||||||||
Medical condition: non-small cell lung cancer (NSCLC), colorectal carcinoma (CRC), salivary gland cancers, papillary thyroid cancer, melanoma, and sarcomas | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-002845-46 | Sponsor Protocol Number: AL-335-604 | Start Date*: 2017-02-03 | |||||||||||||||||||||
Sponsor Name:Alios BioPharma, Inc. | |||||||||||||||||||||||
Full Title: A Phase 2a, Open-Label Study to Evaluate the Safety, Pharmacokinetics and Efficacy of the Combination of AL-335 and Odalasvir, with or without Simeprevir, in Treatment-Naïve Subjects with Genotype ... | |||||||||||||||||||||||
Medical condition: Chronic Hepatitis C infection | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2021-001726-22 | Sponsor Protocol Number: COLIGROW | Start Date*: 2022-12-12 | |||||||||||
Sponsor Name:Dr. Ignacio Herraiz García | |||||||||||||
Full Title: COok's ballon versus dinoprostone for Labor Induction of term pregnancies with fetal GROWth restriction (COLIGROW study). | |||||||||||||
Medical condition: Induction of term pregnancies with fetal growth restriction. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-001045-21 | Sponsor Protocol Number: FSD-MIC-2022-03 | Start Date*: 2023-04-10 |
Sponsor Name:FUNDACION SANTIAGO DEXEUS FONT | ||
Full Title: A Phase III randomized controlled trial comparing the efficacy, safety and tolerability of two formulations of vaginal micronized progesterone. | ||
Medical condition: Infertility | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2019-001283-30 | Sponsor Protocol Number: SPK-3006-101 | Start Date*: 2020-06-16 | |||||||||||
Sponsor Name:Spark Therapeutics | |||||||||||||
Full Title: Phase 1/2, dose-escalation study to evaluate the safety, tolerability and efficacy of a single intravenous infusion of SPK-3006 in adults with late-onset Pompe disease | |||||||||||||
Medical condition: Pompe Disease (also known as glycogen storage disease type II) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) DE (Trial now transitioned) NL (Ongoing) DK (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
